Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory/airway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and/or monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography. For this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring/treatment (i.e., 2 L O2/min via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \<85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
288
medical devices that provide nasal positive airway pressure ventilation during endoscopy
low flow oxygen though nasal cannula
capnometry measurement
Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz
Graz, Austria
NOT_YET_RECRUITINGDepartment of Internal Medicine 2, University Hospital of St Pölten
Sankt Pölten, Austria
RECRUITINGDifference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the standard management group
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the capnometry group vs. the standard management group
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the capnometry group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the PAP group vs. the control group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the PAP group vs. the capnometry group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the capnometry group vs. the control group
Time frame: during endoscopic retrograde cholangio-pancreatography
Lowest SpO2
Lowest SpO2 values across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Median procedure length
Median procedure length (min) across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Satisfaction with sedation
Endoscopist and patient satisfaction levels concerning the procedure on a Likert scale ("Satisfaction scale" 0-10, 0=worst, 10=best) across the three groups
Time frame: Periprocedural
Rate of sedation-related adverse events
Rate of sedation-related adverse events across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Rate of SCOPE
Rate of a combined endpoint of serious adverse events and clinical outcomes (SCOPE) across the three groups SCOPE (serious adverse events and clinical outcomes in procedural endoscopy) includes: 30-day all-cause mortality, cardiopulmonary resuscitation1, unplanned intubation or non-invasive ventilation1, single or multiorgan dysfunction due to an endoscopy-related adverse event (AGREE IVa/IVb), rescue or secondary intervention (endoscopic, surgical, or interventional radiology) due to an endoscopy-related adverse event (AGREE IIIa/b), post-ERCP pancreatitis, or target not reached (with necessity of a secondary procedure) 1 AE occurring after start of the procedure (first dose of sedation administered) until patient leaves recovery room.
Time frame: from ERCP up to 30 days after procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.